Tag: treatment

Burlingame, CA, June 18, 2025 (GLOBE NEWSWIRE) -- The Coherent Market Insights reveals that the Critical Limb Ischemia Treatment Market is estimated to be valued at USD 5.55 Bn in 2025 and is expected to reach USD 10.02 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032. The critical limb ischemia treatment market is projected to experience significant growth during the forecast period. Key factors driving this expansion include the increasing global geriatric population and the rising prevalence of peripheral artery disease, both of which are contributing to a growing demand for effective treatment options.

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of solid tumors and multiple myeloma, today announced key leadership appointments. Alessandra Cesano, MD, PhD, who has served as Consulting Chief Medical Officer since April 2023, will join the company’s Board of Directors. Florian D. Vogl, MD, PhD, has been appointed as Chief Medical Officer (CMO), succeeding Alessandra Cesano on the executive team.

Cardiff, United Kingdom – 18 June 2025 – Draig Therapeutics (“Draig”), a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, today launches from stealth having raised a total of $140 million (£107 million) in the last nine months. The oversubscribed Series A financing was led by Access Biotechnology, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital along with seed investors SV Health Investors, which co-founded the company, and ICG.

～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～